Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoshi Motoya

Showing results (31-40 of 89) with videos related to

Pageof 9
Sort By:
Plos One|April 12, 2019
Correction: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled studySatoshi Motoya, Kenji Watanabe, Haruhiko Ogata, et al.
Inflammatory Intestinal Diseases|December 25, 2025
Long-Term Outcomes and Prognostic Factors for Vedolizumab-Treated Japanese Patients with Ulcerative ColitisShinya Fukushima, Takehiko Katsurada, Takahiro Ito, et al.
Journal of Gastroenterology|December 24, 2013
Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitisYasuo Suzuki, Satoshi Motoya, Hiroyuki Hanai, et al.
Medicine|November 21, 2020
Predicting a rapid response to adalimumab treatment and favorable short-term outcomes through the high platelet count in patients with ulcerative colitis: A multicenter retrospective cohort studyRyosuke Sakemi, Maki Miyakawa, Hiroki Tanaka, et al.
Journal of Gastroenterology|April 21, 2025
Post-marketing surveillance of tofacitinib in patients with ulcerative colitis in Japan: a final report of safety and effectiveness dataKatsuyoshi Matsuoka, Satoshi Motoya, Takayuki Yamamoto, et al.
Journal of Gastroenterology|October 30, 2015
Genetic characteristics of inflammatory bowel disease in a Japanese populationYuta Fuyuno, Keiko Yamazaki, Atsushi Takahashi, et al.
Inflammatory Intestinal Diseases|June 30, 2026
Short- and Long-Term Effectiveness and Safety of Vedolizumab in Crohn's Disease: A Multicenter Retrospective Study from the Hokkaido Phoenix CohortShinsuke Otagiri, Keiya Aoyama, Takehiko Katsurada, et al.
Journal of Gastroenterology and Hepatology|August 19, 2021
Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitisMakoto Naganuma, Kenji Watanabe, Satoshi Motoya, et al.
Inflammatory Intestinal Diseases|September 18, 2018
Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance TherapySatoshi Motoya, Mamoru Watanabe, Kori Wallace, et al.
Inflammatory Intestinal Diseases|December 15, 2023
Effectiveness and Factors Associated with Response to Golimumab in Japanese Patients with Ulcerative Colitis in Real Clinical Practice: The Phoenix StudyDaisuke Hirayama, Satoshi Motoya, Toshifumi Ashida, et al.
Pageof 9

Showing results (31-40 of 89) with videos related to

Sort By:
Pageof 9
Plos One|April 12, 2019
Correction: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled studySatoshi Motoya, Kenji Watanabe, Haruhiko Ogata, et al.
Inflammatory Intestinal Diseases|December 25, 2025
Long-Term Outcomes and Prognostic Factors for Vedolizumab-Treated Japanese Patients with Ulcerative ColitisShinya Fukushima, Takehiko Katsurada, Takahiro Ito, et al.
Journal of Gastroenterology|December 24, 2013
Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitisYasuo Suzuki, Satoshi Motoya, Hiroyuki Hanai, et al.
Medicine|November 21, 2020
Predicting a rapid response to adalimumab treatment and favorable short-term outcomes through the high platelet count in patients with ulcerative colitis: A multicenter retrospective cohort studyRyosuke Sakemi, Maki Miyakawa, Hiroki Tanaka, et al.
Journal of Gastroenterology|April 21, 2025
Post-marketing surveillance of tofacitinib in patients with ulcerative colitis in Japan: a final report of safety and effectiveness dataKatsuyoshi Matsuoka, Satoshi Motoya, Takayuki Yamamoto, et al.
Journal of Gastroenterology|October 30, 2015
Genetic characteristics of inflammatory bowel disease in a Japanese populationYuta Fuyuno, Keiko Yamazaki, Atsushi Takahashi, et al.
Inflammatory Intestinal Diseases|June 30, 2026
Short- and Long-Term Effectiveness and Safety of Vedolizumab in Crohn's Disease: A Multicenter Retrospective Study from the Hokkaido Phoenix CohortShinsuke Otagiri, Keiya Aoyama, Takehiko Katsurada, et al.
Journal of Gastroenterology and Hepatology|August 19, 2021
Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitisMakoto Naganuma, Kenji Watanabe, Satoshi Motoya, et al.
Inflammatory Intestinal Diseases|September 18, 2018
Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance TherapySatoshi Motoya, Mamoru Watanabe, Kori Wallace, et al.
Inflammatory Intestinal Diseases|December 15, 2023
Effectiveness and Factors Associated with Response to Golimumab in Japanese Patients with Ulcerative Colitis in Real Clinical Practice: The Phoenix StudyDaisuke Hirayama, Satoshi Motoya, Toshifumi Ashida, et al.
Pageof 9